SUMOylation Is Required for ERK5 Nuclear Translocation and ERK5-Mediated Cancer Cell Proliferation
Open Access
- 22 March 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6), 2203
- https://doi.org/10.3390/ijms21062203
Abstract
The MAP kinase ERK5 contains an N-terminal kinase domain and a unique C-terminal tail including a nuclear localization signal and a transcriptional activation domain. ERK5 is activated in response to growth factors and stresses and regulates transcription at the nucleus by either phosphorylation or interaction with transcription factors. MEK5-ERK5 pathway plays an important role regulating cancer cell proliferation and survival. Therefore, it is important to define the precise molecular mechanisms implicated in ERK5 nucleo-cytoplasmic shuttling. We previously described that the molecular chaperone Hsp90 stabilizes and anchors ERK5 at the cytosol and that ERK5 nuclear shuttling requires Hsp90 dissociation. Here, we show that MEK5 or overexpression of Cdc37—mechanisms that increase nuclear ERK5—induced ERK5 Small Ubiquitin-related Modifier (SUMO)-2 modification at residues Lys6/Lys22 in cancer cells. Furthermore, mutation of these SUMO sites abolished the ability of ERK5 to translocate to the nucleus and to promote prostatic cancer PC-3 cell proliferation. We also show that overexpression of the SUMO protease SENP2 completely abolished endogenous ERK5 nuclear localization in response to epidermal growth factor (EGF) stimulation. These results allow us to propose a more precise mechanism: in response to MEK5 activation, ERK5 SUMOylation favors the dissociation of Hsp90 from the complex, allowing ERK5 nuclear shuttling and activation of the transcription.Funding Information
- European Regional Development Fund (BFU2007-60268/BMC)
This publication has 58 references indexed in Scilit:
- Brain Specific Kinase-1 BRSK1/SAD-B associates with lipid rafts: modulation of kinase activity by lipid environmentBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2011
- ERK5 signalling in prostate cancer promotes an invasive phenotypeBritish Journal of Cancer, 2011
- Alternative ERK5 regulation by phosphorylation during the cell cycleCellular Signalling, 2010
- Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia ProteinCancer Cell, 2010
- SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 ReceptorScience Signaling, 2010
- ERK5 Activity Is Required for Nerve Growth Factor-induced Neurite Outgrowth and Stabilization of Tyrosine Hydroxylase in PC12 CellsOnline Journal of Public Health Informatics, 2009
- Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic TargetPLOS ONE, 2009
- Effects of MEK5/ERK5 Association on Small Ubiquitin-Related Modification of ERK5: Implications for Diabetic Ventricular Dysfunction After Myocardial InfarctionCirculation Research, 2008
- MAPK signalling: ERK5 versus ERK1/2EMBO Reports, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976